Botulism/Secondary Prevention
MedicalTherapy{{#meta: itemprop="medicalWebPageAudiences" content="patient"}}{{#meta: itemprop="medicalWebPageSpecialities" content="cardiology"}}{{#meta: itemprop="medicalWebPageInfoTypes" content="symptoms,diagnosis,treatment,causes,prognosis,complications"}}
Overview
|
Botulism Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Botulism/Secondary Prevention On the Web |
|
American Roentgen Ray Society Images of Botulism/Secondary Prevention |
|
Risk calculators and risk factors for Botulism/Secondary Prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Michael Maddaleni, B.S., Hafiz M. Ahmed, M.D.[2]
Overview
Secondary prevention focuses on early recognition and treatment of symptomatic botulism to limit disease progression. Prompt public-health notification also supports investigation of suspected exposures and prevention of additional cases. Suspected botulism requires urgent clinical assessment; treatment should not wait for laboratory confirmation.
Secondary Prevention
Early recognition and treatment
- Arrange immediate assessment of suspected symptomatic botulism and contact the state or local health department for emergency consultation.
- When clinical consultation supports botulism, begin appropriate antitoxin treatment promptly without waiting for laboratory confirmation.
- Monitor respiratory function and provide ventilatory support when necessary.
Suspected food sources
- Coordinate investigation of suspected food sources with public-health authorities to support safe source removal and prevent additional cases.
- Discuss collection and submission of suspect foods before disposal. Food remnants and their original containers may be useful for laboratory confirmation.
- Submit suspected foods in their original containers when possible, following public-health instructions.[1]
Public-health reporting
Botulism is a notifiable disease in the United States. Clinicians should promptly notify the state health department of suspected cases, and laboratories should report confirmed cases. Diagnostic testing should be coordinated through public-health authorities.[1]
Exposed persons without symptoms
Management of asymptomatic exposed persons should be discussed with public-health authorities. Routine testing of specimens from asymptomatic persons is generally not performed, and antitoxin is not routinely administered before symptoms develop. Rare exceptional exposures, such as known high-level laboratory exposure, require expert assessment.[1]
References
- ↑ 1.0 1.1 1.2 Centers for Disease Control and Prevention. Clinical Overview of Botulism. April 22, 2024. Accessed October 16, 2026. https://www.cdc.gov/botulism/hcp/clinical-overview/index.html
Related Pages
- Adverse Outcomes:
- Contraindications:
- Duplicate Therapies:
- Indications: {{:}}
- Prevents:
- Treats:Botulism